Table 1 Demographics and clinical characteristics.

Data are shown as number and percentage, n (%). Age is reported in median years (min-max). Days since onset of symptoms is reported as median (min-max). Not all data were collected for HD and recovered individuals. ARDS, acute respiratory distress syndrome; HFNC - NIV, high flow nasal cannula - non-invasive; ECMO, extracorporeal membrane oxygenation.

CharacteristicHDRecoveredModerateSeverea
n127728
Age36 (24-61)30 (20-49)59 (29-64)68 (38-81)
Male6 (46.1)5 (71.4)2 (28.6)19 (67.9)
Race
Black or African American--5 (71.4)16 (57.1)
Asian or Asian American--02 (7.1)
White or Caucasian--2 (14.3)11 (39.2)
Past smoking history--2 (14.3)13 (46.4)
Comorbidity
Obesity--3 (42.9)8 (28.6)
Hypertension--5 (71.4)21 (75)
Diabetes--1 (14.3)7 (25)
Thromboembolic complications 1 (14.3)7 (25)
Coronary artery disease/myocardial infarction--03 (10.7)
Underlying lung diseaseb--4 (57.1)7 (25)
Renal insufficiency/chronic kidney disease--2 (14.2)20 (71.4)
Hyperlipidemia--2 (71.4)14 (50)
Treatment
Hydroxychloroquine--4 (57.1)25 (89.3)
Remdesivirc--1 (14.2)12 (42.9)
Days since onset of symptomsd-27 (17-32)9 (1-16)9 (1-25)
Oxygen therapy/ARDS
Nasal cannula (oxygen < 6L)--3 (42.9)0
HFNC / NIV---4 (4.3)
Ventilator non-ARDS---2 (67.1)
Mild ARDS---3 (10.7)
Moderate ARDS---9 (32.1)
Severe ARDS---10 (35.7)
ECMO---1 (3.6)
Mortality0007 (25)

aTwo severe COVID-19+ individuals were excluded from immunophenotyping and antibody quantification as they displayed clear outlier phenotype due to Rituxan treatment for lymphoma, and acute lymphocytic leukemia, respectively. bUnderlying lung disease includes asthma, chronic obstructive pulmonary disease and interstitial lung disease. cDonors enrolled in a clinical trial to test remdesivir versus placebo. Remdesivir was administered after blood collection. dDays since onset of symptoms accounted from the time of blood collection.